Analyzing Lyell Immunopharma (NASDAQ:LYEL) and Neuphoria Therapeutics (NASDAQ:NEUP)

Neuphoria Therapeutics (NASDAQ:NEUP) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Profitability

This table compares Neuphoria Therapeutics and Lyell Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-38.31%	-28.92%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Earnings and Valuation

This table compares Neuphoria Therapeutics and Lyell Immunopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$1.17 million	15.43	-$13.45 million	($6.22)	-0.54
Lyell Immunopharma	$40,000.00	5,334.88	-$274.45 million	($12.83)	-0.68

Neuphoria Therapeutics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 66.0% of Lyell Immunopharma shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Neuphoria Therapeutics and Lyell Immunopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	2	0	0	1.67
Lyell Immunopharma	1	1	6	1	2.78

Neuphoria Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 109.83%. Lyell Immunopharma has a consensus target price of $40.86, indicating a potential upside of 369.08%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Neuphoria Therapeutics.

Summary

Neuphoria Therapeutics beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.